Other Earnings and Cash Flow Stats:
BeiGene Ltd. ( BGNE ) Net Income TTM ($MM) is -860.46
BeiGene Ltd. ( BGNE ) Operating Income TTM ($MM) is -872.57
BeiGene Ltd. ( BGNE ) Owners' Earnings Annual ($MM) is 0.00
BeiGene Ltd. ( BGNE ) Current Price to Owners' Earnings ratio is 0.00
BeiGene Ltd. ( BGNE ) EBITDA TTM ($MM) is -727.23
BeiGene Ltd. ( BGNE ) EBITDA Margin is -11.30%
Capital Allocation:
BeiGene Ltd. ( BGNE ) has paid 0.00 dividends per share and bought back -1273.545561 million shares in the past 12 months
BeiGene Ltd. ( BGNE ) has reduced its debt by 365.344 million USD in the last 12 months
Capital Structure:
BeiGene Ltd. ( BGNE ) Interest-bearing Debt ($MM) as of last quarter is 237
BeiGene Ltd. ( BGNE ) Annual Working Capital Investments ($MM) are 544
BeiGene Ltd. ( BGNE ) Book Value ($MM) as of last quarter is 3436
BeiGene Ltd. ( BGNE ) Debt/Capital as of last quarter is 6%
Other Balance Sheet Stats:
BeiGene Ltd. ( BGNE ) has 2701 million in cash on hand as of last quarter
BeiGene Ltd. ( BGNE ) has 2025 million of liabilities due within 12 months, and long term debt 1051 as of last quarter
BeiGene Ltd. ( BGNE ) has 1380 common shares outstanding as of last quarter
BeiGene Ltd. ( BGNE ) has 0 million USD of preferred stock value
Academic Scores:
BeiGene Ltd. ( BGNE ) Altman Z-Score is 61.46 as of last quarter
BeiGene Ltd. ( BGNE ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
BeiGene Ltd. ( BGNE ) largest shareholder is owning shares at 0.00 ($MM) value
Wang Xiaodong(an insider) Sold 300 shares of BeiGene Ltd. ( BGNE ) for the amount of $58700.01 on 2024-12-10
17.79% of BeiGene Ltd. ( BGNE ) is held by insiders, and 44.83% is held by institutions
BeiGene Ltd. ( BGNE ) went public on 2016-02-03
Other BeiGene Ltd. ( BGNE ) financial metrics:
FCF:-1004.52
Unlevered Free Cash Flow:0.00
EPS:-0.35
Operating Margin:-12.01
Gross Profit Margin:82.98
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-14.13
Beta:0.57
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BeiGene Ltd. ( BGNE ) :
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
DISCLAIMER
This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.